Top Health Tools
Top Health Tools

Top Reports
Top Reports
Top Articles
Top Articles

Top Reviews
Top Reviews
Researchers Detect Reassortment of H1N1 Virus: Drug Makers Announce New H5N1 Vaccine

Just as Japan's largest drug maker admits developing a vaccine for H5N1, Hong Researchers have detected a reassortment of the H1N1 flu virus.

Hong Kong researchers identified that A/H1N1 influenza virus has undergone genetic reassortment to give rise to a novel A/H1N1 virus on pigs, according to a study done by the University of Hong Kong which made the result public.

The new virus has genes from the A/H1N1 influenza virus and other pig influenza viruses, told the research findings, which demonstrated that A/H1N1 flu virus may change in unpredictable ways in pigs and such viruses may have relevance to global public health.

While there is no indication that the particular reassortant virus detected by the university poses an immediate threat to humans, the study result emphasizes the need for systematic surveillance of flu viruses in pigs worldwide, the university said.

"Our findings emphasize the need for animal and public health authorities to work closely together to maintain surveillance of influenza viruses in pigs so that any unexpected changes in these viruses are rapidly detected and their significance rapidly evaluated," said Malik Peiris, Professor of the university's Department of Microbiology.

He also reminded the public not to panic about eating pork, saying that pigs and pork products do not pose an influenza-threat to humans provided good hygiene measures are maintained and pork is well cooked.

The research has been published in an international scientific journal -- "Science".

Meanwhile, Japan's largest drugmaker Takeda Pharmaceutical Co will resume production of influenza vaccines after more than a decade, using technology from U.S. firm Baxter International Inc, the Nikkei business daily reported.

The Osaka-based firm will initially develop a vaccine to immunize against H5N1 avian flu, it said.

The company also expects to receive 1 billion yen to 3 billion yen in Health Ministry subsidies for the effort, the paper said.


STAY CONNECTEDNewsletter | RSS | Twitter | YouTube |
This site is owned and operated by 1999-2018. All Rights Reserved. All content on this site may be copied, without permission, whether reproduced digitally or in print, provided copyright, reference and source information are intact and use is strictly for not-for-profit purposes. Please review our copyright policy for full details.
volunteerDonateWrite For Us
Stay Connected With Our Newsletter